The phase III IMvigor010 study assessing Tecentriq as an adjuvant (after surgery) monotherapy treatment has not achieved its primary endpoint of disease-free survival (DFS) compared against observation in
Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or locally advanced epithelioid sarcoma sarcoma not
The company redeemed its priority review voucher for the NDA submission. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or
The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing risdiplam in infants aged between one and seven months
The investment efforts were led by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a fifteen-year veteran in the biopharmaceutical space. Dr.
North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 new jobs in the Durham region. The new job
Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat EDS in adults living with narcolepsy or OSA and the only licensed therapy in the
Imfinzi is a human monoclonal antibody that binds to PD-L1 and restricts the interaction of PD-L1 with PD-1 and CD80, helping to oppose the tumour’s immune-evading tactics and
Safety findings from the first cohort were reviewed by the DEC. The Principal Medical Investigator and Sponsor agreed it acceptable to increase the dose of Brilacidin for administration
DRG is engaged in offering high-value data, analytics and insights products and services to the healthcare industry. The deal includes $900m in cash, as well as issuing of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.